About AVT
Browse Articles
Customer Services


Novel agents for the treatment of HIV-2 infection

Kevin Peterson, Sarah Rowland-Jones

Corresponding author name: Kevin Peterson
Corresponding author e-mail: kpeterson@itg.be

Citation: Antiviral Therapy 2012; 17:435-438
doi: 10.3851/IMP2031

Date accepted: 11 September 2011
Date published online: 25 January 2012


Many of the antiretrovirals used against HIV-1 are either ineffective or less effective in HIV-2 infection. There is in vitro evidence of the potency of maraviroc and several investigational agents against HIV-2. We conclude that, whilst specific boosted protease inhibitors combined with nucleoside analogues should still be considered the mainstays of HIV-2 treatment, maraviroc, T-1249, TAK-779 and AMD3100, as well as raltegravir, could contribute to regimens for treatment-experienced individuals. Factors bearing on the use and timing of these alternative agents are discussed.


Copyright © Nucleus Global 2017. Part of Nucleus Global.
Design and Technology by Nucleus Global
Company registration No. 321 0712 (England & Wales). Registered Office address: Admiral House 76-78 Old Street, London EC1V 9AZ.